Biological properties of hypoxia-related gene expression models/signatures on clinical benefit of anti-EGFR treatment in two head and neck cancer window-of-opportunity trials.

•Biomarkers are analyzed in two WOO anti-EGFR studies on pre- and post-treatment HNSCC tumors.•In pre treatment samples, hypoxia signatures positively associated with PET response to anti-EGFR.•In pre treatment samples, hypoxia traits were negatively correlated to the immunoscore.•Signature’s down-modulation in post-treatment samples confirmed the anti-EGFR activity.